Journal
IMMUNOTHERAPY
Volume 3, Issue 8, Pages 945-947Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/IMT.11.94
Keywords
FOXO3; tolerance; tumor-associated dendritic cell
Categories
Funding
- Ministry of Education, Culture, Sports, Science and Technology in Japan
- Grants-in-Aid for Scientific Research [22659075, 21590401, 21249025, 22659235] Funding Source: KAKEN
Ask authors/readers for more resources
Evaluation of: Watkins SK, Zhu Z, Riboldi E et al. FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J. Clin. Invest. 121(4), 1361-1372 (2011). Tumor-associated dendritic cells (TADCs) have been described as immune-suppressive cells in cancers, and part of the molecular mechanisms has emerged. The transcription factor FOXO3 - one of the tumor suppressors - is overexpressed in TADCs that have been infiltrated in human prostate cancers and TRAMP mouse model of prostate cancers, and induces the expression of immune-suppressive genes including indoleamine-2,3-dioxygenase (IDO1), arginase (ARG1) and TGF-beta. Adoptive transfer of T helper cells or silencing of FOXO3 by siRNAs repressed the expression of FOXO3 gene and inhibited the tolerogenicity of TADCs. Therefore, inhibition of FOXO3 signals might be a clue for improvement of cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available